Serological identification of fast progressors of structural damage with rheumatoid arthritis

Extracellular Matrix Remodeling: The Common Denominator in Connective Tissue DiseasesPossibilities for Evaluation and Current Understanding of the Matrix as More Than a Passive Architecture, but a Key Player in Tissue Failure

(2012) Morten A. Karsdal et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction

(2011) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Modulation of matrix metalloproteinase production by rheumatoid arthritis synovial fibroblasts after cadherin 11 engagement

(2011) Erika H. Noss et al.   ARTHRITIS AND RHEUMATISM

A novel marker for assessment of liver matrix remodeling: An enzyme-linked immunosorbent assay (ELISA) detecting a MMP generated type I collagen neo-epitope (C1M)

(2011) DJ. Leeming et al.   BIOMARKERS

Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study

(2011) Anne C. Bay-Jensen et al.   RHEUMATOLOGY INTERNATIONAL

Biomarkers in early rheumatoid arthritis: longitudinal associations with inflammation and joint destruction measured by magnetic resonance imaging and conventional radiographs

(2010) S. W. Syversen et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

(2010) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Validation of an automated intact N-terminal propeptide of type I procollagen (PINP) assay

(2010) Marja-Kaisa Koivula et al.   CLINICAL BIOCHEMISTRY

Novel combinations of Post-Translational Modification (PTM) neo-epitopes provide tissue-specific biochemical markers—are they the cause or the consequence of the disease?

(2010) Morten Asser Karsdal et al.   CLINICAL BIOCHEMISTRY

Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis

(2010) Kyoung Soo Kim et al.   RHEUMATOLOGY INTERNATIONAL

Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis

(2009) L. H. D. van Tuyl et al.   ANNALS OF THE RHEUMATIC DISEASES

Biochemical markers and the FDA Critical Path: How biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development

(2009) M.A. Karsdal et al.   BIOMARKERS

Cartilage and Bone Biomarkers in Rheumatoid Arthritis: Prediction of 10-year Radiographic Progression

(2009) S. W. SYVERSEN et al.   JOURNAL OF RHEUMATOLOGY

Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study

(2008) I Hafstrom et al.   ANNALS OF THE RHEUMATIC DISEASES